Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis?

J Crohns Colitis. 2024 Mar 1;18(3):337-338. doi: 10.1093/ecco-jcc/jjad167.

Authors

Xavier Roblin¹, Stephane Paul²

Affiliations

¹ Department of Gastroenterology, University Hospital of Saint-Etienne, Saint-Etienne, France.
² Immunology laboratory, iBioThera reference center, CIC1408, University Hospital of Saint-Etienne, Saint-Etienne, France; CIRI (Centre International de Recherche en Infectiologie), Université Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Université Jean Monnet de Saint-Etienne, Saint-Etienne, France.

PMID: 37847799
DOI: 10.1093/ecco-jcc/jjad167

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adalimumab / therapeutic use
Anti-Inflammatory Agents / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Colitis, Ulcerative* / drug therapy
Humans
Prospective Studies

Substances

Adalimumab
Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized